TrialDisease markers2022

Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, and Their Variations as a Basis for a Prediction Model in Advanced NSCLC Patients Receiving Anlotinib.

Tian Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.